INTRODUCTION
============

Brain metastases (BM) are a critical complication of non-small cell lung cancer (NSCLC), because this is the most common primary cancer leading to BM. The presence of BM in patients with NSCLC is associated with poor prognosis, with a median survival of only 7 months recorded for these patients, despite whole-brain radiation therapy \[[@b1-kjim-2015-158]\].

NSCLC with epidermal growth factor receptor (*EGFR*) mutations comprises a distinct subgroup of the disease, associated with significant sensitivity to *EGFR*-tyrosine kinase inhibitors (TKIs) and improved overall and progression-free survival when treated with *EGFR*-TKIs \[[@b2-kjim-2015-158]-[@b4-kjim-2015-158]\]. Although BM occurs in a substantial number of NSCLC cases with *EGFR* mutations, the relationship between *EGFR* mutations and the risk of BM occurrence as well as the associated prognosis is not clear, and only retrospective studies in this regard are currently reported in the literature. In several of these retrospective studies, *EGFR* mutations have been found to be associated with a higher risk of BM development \[[@b5-kjim-2015-158],[@b6-kjim-2015-158]\] as well as longer overall median survival from the time of BM diagnosis than those with *EGFR* wild type (WT) \[[@b6-kjim-2015-158]-[@b11-kjim-2015-158]\]. However, the results from these studies are inconsistent \[[@b12-kjim-2015-158],[@b13-kjim-2015-158]\]. Although relatively few studies have examined the time from the diagnosis of NSCLC to BM development, the time was estimated from the initial diagnosis of NSCLC, irrespective of the stage, and not from the time of diagnosis of metastatic NSCLC.

The aim of this study was to investigate the incidence, timing, and median overall survival (OS) associated with BM in patients with metastatic NSCLC harboring *EGFR* mutations compared to those exhibiting WT *EGFR*.

METHODS
=======

Patients
--------

We retrospectively reviewed the medical records of patients from a single healthcare center who were diagnosed with NSCLC stage IV (according to the 7th American Joint Committee on Cancer \[AJCC\] Cancer Staging System) between January 2010 and August 2013 whose *EGFR* mutational status was known. Every patient underwent brain magnetic resonance imaging when first diagnosed with metastatic lung cancer, irrespective of the presence of symptoms of BM. During the course of the disease, brain imaging was performed only when BM were suspected. Data of clinical characteristics including sex, age, Eastern Cooperative Oncology Group performance status, history of smoking, the date of diagnosis of BM, symptoms of BM, treatment, and survival time were obtained from medical records or from the records of the national health insurance system. Patient observation continued through May 2015. This study was approved by the Institutional Review Board of Gachon University Gil Medical Center.

*EGFR* mutational analysis
--------------------------

Tumor DNA was acquired from paraffin-embedded cancer tissue and amplified by polymerase chain reaction (PCR). For the mutational analysis of the *EGFR* gene (exons 18-21) in the latter samples, direct sequencing was performed on samples collected in 2011 and 2012. In 2010, *EGFR* mutation analysis was not routine and was performed at the physician's discretion. Since 2011, it has been performed in nearly every patient with metastatic NSCLC with sufficient tumor DNA. Prior to 2013, the Big Dye Terminator v 1.1 kit, together with an ABI 3130xl genetic analyzer (both from Applied Biosystems, Foster City, CA, USA), was used for bidirectional sequencing of the tumor DNA samples. Since 2013, the peptide nucleic acid (PNA)-mediated real-time PCR clamping method was used, involving the PNA Clamp TM *EGFR* Mutation Detection Kit (PANAGENE Inc., Daejeon, Korea).

Statistical analysis
--------------------

Categorical variables were compared using a chi-square test. For the patients who did not have BM at initial diagnosis, time to brain metastases (TTBM) was calculated from the date of metastatic NSCLC diagnosis to the date of the first occurrence of BM. OS of a patient was defined as the time between diagnosis of metastatic NSCLC and death of the patient (from any cause) or last date of clinic visit. BM-OS, on the other hand, was calculated from the time of diagnosis of the first BM to the time of death of the patient (from any cause) or last date of clinic visit. Survival time was estimated by the Kaplan-Meier method and was compared with a log-rank test. Follow-up duration was estimated using the Kaplan-Meier estimate of potential follow-up \[[@b14-kjim-2015-158]\].

RESULTS
=======

Patient characteristics
-----------------------

We retrospectively identified 259 patients with metastatic NSCLC with known *EGFR* mutation status using available medical records. *EGFR* mutations were found in 73 patients. The most common *EGFR* mutations were exon 19 deletions (n = 41, 56.2%) and the exon 21 point mutation L858R (n = 23, 31.5%). Most patients had adenocarcinoma (n = 180, 70.0%). The clinical characteristics of these patients are listed in [Table 1](#t1-kjim-2015-158){ref-type="table"}.

BM development and *EGFR* mutations
-----------------------------------

Sixty-seven patients were diagnosed with BM. The median estimated potential follow-up duration for those patients with BM was 41.4 months. During the disease course, 37.0% (n = 27) of patients with *EGFR* mutations and 21.5% (n = 40) of those with *EGFR* WT developed BM (*p* \< 0.006). Among 27 BM patients with *EGFR* mutations, 25 patients had the L858R mutation or deletion in exon 19, while the remaining two patients had the G719X mutation in exon 18.

Among 67 patients with BM, the brain was the first site of metastasis in 47 patients (70.1%). Synchronous BM was significantly more common in patients with *EGFR* mutations (n = 20, 27.4% of all 73 patients with *EGFR* mutations) than in patients with *EGFR* WT (n = 27, 14.5% of 186 patients with *EGFR* WT, *p* \< 0.009) ([Table 1](#t1-kjim-2015-158){ref-type="table"}). The prevalence of metachronous BM, however, did not appear to differ according to *EGFR* mutational status. In patients with metachronous development of BM, TTBM did not differ significantly according to *EGFR* mutational status (median TTBM 13.4 months for *EGFR* mutations vs. 8.8 months for *EGFR* WT, *p* \< 0.229) ([Fig. 1](#f1-kjim-2015-158){ref-type="fig"}).

The characteristics of BM by *EGFR* mutational status are displayed in [Table 2](#t2-kjim-2015-158){ref-type="table"}. Patients with *EGFR* mutation type (MT) were more likely to belong to the female sex, and had better performance status compared to patients with *EGFR* WT. The presence of symptoms of BM, the number of BM lesions, and the treatment were not significantly different between *EGFR* MT and *EGFR* WT patients.

Association between *EGFR* mutations and survival following BM
--------------------------------------------------------------

At the time of this analysis, 52 of the 67 patients (77.6%) with BM had died, 14 patients remained alive, and one patient was lost to follow-up. The median OS of all 67 BM patients was 13.7 months. OS did not differ significantly according to the timing of BM development (median OS 12.1 months for the synchronous BM group vs. 14.0 months for the metachronous BM group). However, the median BM-OS in those patients who displayed metachronous BM (n = 20) was only 2.5 months.

*EGFR* mutations were associated both with longer OS (median OS 28.6 months in *EGFR* MT vs. 9.1 months in *EGFR* WT, *p* \< 0.001) ([Fig. 2A](#f2-kjim-2015-158){ref-type="fig"}) and longer BM-OS (median BM-OS 25.7 months in *EGFR* mutations vs. 3.8 months in *EGFR* WT, *p* \< 0.001) ([Fig. 2B](#f2-kjim-2015-158){ref-type="fig"}). In patients with synchronous BM, the survival after BM development was longer in *EGFR* MT than in *EGFR* WT patients (median BM-OS 25.7 months vs. 6.8 months, respectively; *p* \< 0.001) ([Fig. 3A](#f3-kjim-2015-158){ref-type="fig"}). In patients with metachronous BM, BM-OS in patients with *EGFR* mutations tended towards longer OS (median BM-OS 14.5 months for *EGFR* MT vs. 2.5 months for *EGFR* WT, *p* = 0.230) ([Fig. 3B](#f3-kjim-2015-158){ref-type="fig"}), but it did not reach statistical significance. Cause of death could be determined for 28 (53.8%) of the original cohort of NSCLC patients with BM. Most patients (n = 12) had systemic progression with stable BM at the time of death. Seven patients died of progression of BM at time of death (one patient with *EGFR* MT vs. six with *EGFR* WT).

DISCUSSION
==========

The current study demonstrated that *EGFR* mutations in metastatic NSCLC patients were associated with a high likelihood of BM, and that such mutations were linked to higher median survival after BM development, especially in patients with synchronous BM development. On the other hand, in patients with metachronous BM, TTBM was not significantly different according to *EGFR* mutation status.

Most studies on BM and *EGFR* mutations, including ours, assess *EGFR* mutations from extracranial tumor tissue, which has been validated by Luo et al. \[[@b13-kjim-2015-158]\]. They demonstrated a high concordance rate (93.3%) of *EGFR* mutational status between BM and extracranial tumor tissue.

In line with studies \[[@b5-kjim-2015-158],[@b6-kjim-2015-158],[@b10-kjim-2015-158]\] that reported synchronous BM presence in 11% to 16% of stage I to IV patients, more commonly in patients with *EGFR* mutations, our study showed that *EGFR* mutations were associated with a higher incidence of BM. Synchronous BM was present in 18.1% of the patients with stage IV NSCLC and was more common in patients with *EGFR* mutations (27.4%) than in those with *EGFR* WT (14.5%). This increased risk of BM associated with *EGFR* mutations has also previously been observed in patients with NSCLC of earlier stages who underwent curative resection \[[@b5-kjim-2015-158],[@b6-kjim-2015-158]\]. The reasons for the high propensity of BM in *EGFR* mutant NSCLC remain unclear. Plausible underlying mechanisms for the increase in BM include activation of *EGFR* or MET receptor tyrosine kinase-associated signaling pathways, as has previously been reported in both NSCLC and breast cancer. In particular, *EGFR* activation in breast cancer cells has been shown to be associated with a higher capability of migration and invasion to the brain \[[@b15-kjim-2015-158]\], and Met protein activation has been demonstrated to be associated with a higher risk of BM in patients with NSCLC \[[@b16-kjim-2015-158]\].

In agreement with our results, for patients with BM from primary NSCLC, *EGFR* mutations have been reported to be associated with better survival from the time of BM development (15 to 25 months) \[[@b6-kjim-2015-158]-[@b10-kjim-2015-158]\] than patients with WT *EGFR* (7 months) \[[@b1-kjim-2015-158]\]. It is not clear whether the prolonged BM-OS in patients with *EGFR* mutations is due to the improved OS from better control of extracranial disease with *EGFR*-TKIs, due to the favorable role of *EGFR*-TKIs in treating BM itself, or due to differences in the biology and behavior between *EGFR* mutated and WT NSCLC cells. Regarding the efficacy of *EGFR*-TKIs on intracranial disease in NSCLC, there is a substantial intracranial response \[[@b17-kjim-2015-158],[@b18-kjim-2015-158]\]; however, central nervous system (CNS) penetration of gefitinib or erlotinib is limited in pharmacokinetic studies \[[@b19-kjim-2015-158],[@b20-kjim-2015-158]\]. The role of *EGFR*-TKIs in the prevention of BM progression is supported by an observation of a lower rate of CNS progression (hazard ratio, 0.56) in NSCLC patients with activating *EGFR* mutations treated with *EGFR*-TKIs compared with those treated with conventional chemotherapy \[[@b21-kjim-2015-158]\]. It must be stated; however, that it is difficult to distinguish between the effects of systemic and local treatment in published retrospective studies.

Although *EGFR* mutations are associated with better survival in populations with BM, BM itself remains associated with lower survival compared to those without BM in the patient group with *EGFR* mutations \[[@b22-kjim-2015-158]\]. Prognostic assessment is especially important in patients with BM in order to implement suitable treatment strategies. *EGFR* mutations have an additional prognostic impact independent of well-known prognostic indices such as the lung-specific graded prognostic assessment (GPA) index \[[@b8-kjim-2015-158]\] or recursive partitioning analysis class \[[@b7-kjim-2015-158]\]. Incorporation of *EGFR* mutational status into the prognostic estimation of BM from NSCLC should be considered in the future, in the same manner as for the molecular subtypes of breast cancer, which has been included in breast-specific GPA scoring criteria \[[@b1-kjim-2015-158]\].

Interestingly, we found that the favorable effect of *EGFR* mutations on survival from BM diagnosis was lacking in NSCLC patients who developed metachronous BM, which was in agreement with previous findings by Shin et al. \[[@b5-kjim-2015-158]\]. This phenomenon may be due to different mechanisms or drug sensitivities between synchronous and metachronous BM or it may be because diagnosis of metachronous BM usually accompanies CNS symptoms, while synchronous BMs are often asymptomatic. In contrast, overall risk of BM was higher in *EGFR* mutant NSCLC patients \[[@b5-kjim-2015-158],[@b6-kjim-2015-158],[@b10-kjim-2015-158]\]. In those with metachronous BM, TTBM development seemed to be longer in *EGFR* mutant NSCLC than in *EGFR* WT \[[@b6-kjim-2015-158],[@b7-kjim-2015-158]\], which was observed in this study too. In former studies \[[@b6-kjim-2015-158],[@b7-kjim-2015-158]\], TTBM was calculated from the initial diagnosis of NSCLC stage I to IV, which was estimated more uniformly from the initial diagnosis of metastatic stage in this study. The opposite characteristics of *EGFR* MT, namely, a higher risk of synchronous BM yet a longer TTBM, may be due to delayed BM progression owing to *EGFR*-TKI treatment in *EGFR* mutant NSCLC \[[@b7-kjim-2015-158],[@b21-kjim-2015-158]\].

In conclusion, we report that *EGFR* mutations in metastatic NSCLC were associated with a greater frequency of synchronous BM and with significantly longer survival from the time of BM diagnosis when compared with *EGFR* WT, the latter trend being more pronounced in those patients with synchronous versus metachronous BM. We therefore propose that *EGFR* mutational status should be considered when assessing possible treatment strategies for BM in patients with NSCLC.

KEY MESSAGE
===========

1\. Synchronous brain metastases were more common in metastatic non-small cell lung cancer (NSCLC) patients with epidermal growth factor receptor (*EGFR*) mutations than in those with wild type *EGFR*.

2\. *EGFR* mutations were associated with significantly longer overall survival from the time of brain metastases diagnosis in metastatic NSCLC patients.
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###### 

Patient characteristics

  Characteristic            Total (n = 259)   *EGFR* MT (n = 73)   *EGFR* WT (n = 186)   *p* value
  ------------------------- ----------------- -------------------- --------------------- -----------
  Sex                                                                                    
   Male                     167 (64.5)        27 (37.0)            140 (75.3)            \< 0.001
   Female                   92 (35.5)         46 (63.0)            46 (24.7)             
  Age, yr                   68 (37--89)       66 (37--87)          68 (37--89)           0.155
  Smoking history                                                                        \< 0.001
   Never-smoker             106 (40.9)        48 (65.8)            58 (31.2)             
   Former smoker            68 (26.3)         15 (20.5)            53 (28.5)             
   Current smoker           85 (32.8)         10 (13.7)            75 (40.3)             
  Pathologic histology                                                                   \< 0.001
   Adenocarcinoma           180 (70.0)        64 (87.7)            116 (62.4)            
   Squamous                 40 (15.4)         2 (2.7)              38 (20.4)             
   Large cell               27 (10.4)         6 (8.2)              21 (11.3)             
   Other                    12 (4.6)          1 (1.4)              11 (5.9)              
  Type of *EGFR* mutation                                                                
   Deletion in exon 19                        41 (56.2)                                  
   L858R                                      23 (31.5)                                  
   Others                                     9 (12.3)                                   
  Brain metastases          67 (25.9)         27 (37.0)            40 (21.5)             \< 0.006
   Synchronous BM                             20 (27.4)            27 (14.5)             \< 0.009
   Metachronous BM                            7 (9.6)              13 (7.0)              \< 0.578

Values are presented as number (%) or median (range).

EGFR, epidermal growth factor receptor; MT, mutation type; WT, wild type; BM, brain metastasis.

###### 

Characteristics of patients developed brain metastases

  Characteristic          Total (n = 67)   *EGFR* MT (n = 27)   *EGFR* WT (n = 40)   *p* value
  ----------------------- ---------------- -------------------- -------------------- -----------
  Sex                                                                                0.014
   Male                   35 (52.2)        9 (33.3)             26 (65.0)            
   Female                 32 (47.8)        18 (66.6)            14 (35.0)            
  Age, yr                 68 (41--85)      64 (45--83)          68 (41--85)          0.335
  ECOG PS                                                                            0.040
   0--1                   56 (83.6)        26 (96.3)            30 (75.0)            
   2--3                   11 (16.4)        1 (3.7)              10 (25.0)            
  Smoking history                                                                    0.013
   Never-smoker           31 (46.3)        17 (63.0)            14 (35.0)            
   Former smoker          16 (23.9)        7 (25.9)             9 (22.5)             
   Current smoker         20 (29.9)        3 (11.1)             17 (42.5)            
  Pathologic histology                                                               0.085
   Adenocarcinoma         47 (70.1)        23 (85.2)            24 (60.0)            
   Squamous               6 (9.0)          0                    6 (15.0)             
   Large cell             10 (14.9)        3 (11.1)             7 (17.5)             
   Other                  4 (6.0)          1 (3.7)              3 (7.5)              
  Symptoms of BM                                                                     0.803
   Absent                 30 (44.8)        13 (48.1)            17 (42.5)            
   Present                37 (55.2)        14 (51.9)            23 (57.5)            
  *EGFR* TKI treatment                                                               
   1st line                                13 (48.1)                                 
   2nd line                                11 (40.7)                                 
   3rd line                                2 (7.4)                                   
   None                                    1 (3.7)                                   
  Timing of BM                                                                       0.599
   Synchronous            47 (70.1)        20 (74.1)            27 (67.5)            
   Metachronous           20 (29.9)        7 (25.9)             13 (32.5)            
  No. of lesions                                                                     0.741
   Single                 19 (28.4)        6 (22.2)             13 (32.5)            
   2--4                   11 (16.4)        5 (18.5)             6 (15.0)             
   ≥ 5                    37 (55.2)        16 (59.3)            21 (52.5)            
  Local treatment of BM                                                              0.896
   WBRT                   37 (55.2)        15 (55.6)            22 (55.0)            
   SRS                    11 (16.4)        5 (18.5)             6 (15.0)             
   Surgery                4 (6.0)          2 (7.4)              2 (5.0)              
   None                   15 (22.4)        5 (18.5)             10 (25.0)            

Values are presented as number (%) or median (range).

EGFR, epidermal growth factor receptor; MT, mutation type; WT, wild type; ECOG PS, Eastern Cooperative Oncology Group Performance status; BM, brain metastasis; TKI, tyrosine kinase inhibitor; WBRT, whole brain radiotherapy; SRS, stereotactic radiosurgery.
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